Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma Summary Plasmapheresis, a procedure that filters blood, has shown promise in overcoming resistance to anti-BCMA immunotherapies for multiple myeloma. These immunotherapies target BCMA, a protein on myeloma cells. However, some patients exhibit primary…

Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma Summary Real-world data on idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) CAR-T therapy for multiple myeloma reveals distinct immune correlates associated with efficacy. While both products target BCMA, key…